Durata Therapeutics Focus Group
Durata Therapeutics graciously supports the Society of Emergency Medicine Physician Assistants (SEMPA). As part of their support benefits, Durata Therapeutics is hosting a Focus Group with 15 participants during the SEMPA Conference on Monday, March 24, 3:30 PM – 5:00 PM. An honorarium of $150 will be provided by Durata Therapeutics to each participant who attends the entire focus group time period.
Participation Eligibility: An eligible participant must meet all of the following eligibility criteria:
- Practice full time as an emergency medicine physician assistant;
- Have an interest in the management of acute bacterial skin and skin structure infections (ABSSSI);
- Have at least 3 years of practice experience in an emergency department;
- Currently practice in only one facility.
If you meet all of these requirements, you are eligible to complete the brief survey via the link provided below to be considered as a participant in the Durata Therapeutics Focus Group. Durata Therapeutics will select and confirm Emergency Medicine Physician Assistants who meet their demographic criteria.
Focus Group Topics:
- Understand how the treatment of ABSSSI (e.g. cellulitis ± abscess, wound and surgical site infections) would rank relative to an emergency medicine organization’s overall strategy to optimize the cost and quality of care;
- Understand the relevance and value of shifting the site of care for the treatment of ABSSSI from inpatient to outpatient settings (e.g. avoidable inpatient admissions);
- Discuss which factors, metrics and evidence are necessary to engage and motivate emergency medicine’s understanding and willingness to change practice in the treatment of ABSSSI.
Dalbavancin is a new antibacterial currently in late-stage clinical development. It is being studied to treat acute bacterial skin andskin structure infections (ABSSSI) caused by susceptible Gram-positivebacteria. The microbiologic profile of dalbavancin demonstrates bactericidal activity against a broad range of bacteria, such as Staphylococcusaureus (including methicillin-resistant strains) and Streptococcuspyogenes, as well as certain other streptococcal species.
Dalbavancin is a second generation, semi-syntheticlipoglycopeptide, which consists of lipophilic side-chains attached toglycopeptides. If approved, dalbavancin would be the first drug for ABSSSI dosed and administered with a once-weekly, 30 minute infusion through aperipheral IV.
In the recently completed Phase 3 clinical trial program for an acute bacterial skin and skin structure infection (ABSSSI) indication,patients were treated for two weeks either with intravenous dalbavancin once-weekly (1000 mg on Day 1 followed by 500 mg on Day 8; total of two doses)or with intravenous vancomycin (1000 mg or 15 mg/kg every 12 hours) with the option to switch to oral linezolid after three days (total of 28 doses for up to 14 days).
Durata Therapeutics, Inc. submitted a new drug applicationfor dalbavancin with the U.S. Food and Drug Administration at the end of September 2013, which was accepted for priority review.
Focus Group Details:
Date, Time, Location: Monday,March 24, 3:30 PM – 5:00 PM, at the New Orleans Marriott, in the Gallerie 1room. (Light refreshments will be provided.)
Time Commitment Requirement: One hourand 30 minutes. A participant must be present for the entire focus group time period to be eligible for receipt of the honorarium.
Honorarium: $150 per participant.Durata Therapeutics is responsible for payment of all participant honorariums.Focus group participants must provide a tax ID or social security number and sign a form to receive payment by mail from Durata Therapeutics.
Location Address: New Orleans Marriott, 555 Canal Street (same location where the SEMPA Conference will beheld)
Deadline to Complete Survey: February 24
Confirmation of Participation: March 5 - 7; Durata Therapeutics will contact only the survey respondents whoare selected for the Focus Group by phone/email to confirm participation in thefocus group. If you do not receive notification from Durata Therapeutics,then you were not selected.
Please click on the link below to complete the brief survey. Thank you for your consideration.
Focus Group Participation Survey Link